Targeting the TLR3–NR2F6 axis may thus represent a promising therapeutic strategy to restore the urothelial barrier and alleviate lower urinary tract symptoms in IC/BPS patients.27 This evidence concerns the gene TLR3 and Bartsocas-Papas syndrome 1.